Data from Oncolytic Herpes Virus Armed with Vasculostatin in Combination with Bevacizumab Abrogates Glioma Invasion via the CCN1 and AKT Signaling PathwaysYusuke Tomita, Isao Date, Kazuhiko Kurozumi et al.|Unknown|2023Cited by 0
Supplementary Figure 3 from Oncolytic Herpes Virus Armed with Vasculostatin in Combination with Bevacizumab Abrogates Glioma Invasion via the CCN1 and AKT Signaling PathwaysYusuke Tomita, Isao Date, Kazuhiko Kurozumi et al.|Unknown|2023Cited by 0
Supplementary Figure 2 from Oncolytic Herpes Virus Armed with Vasculostatin in Combination with Bevacizumab Abrogates Glioma Invasion via the CCN1 and AKT Signaling PathwaysYusuke Tomita, Isao Date, Kazuhiko Kurozumi et al.|Unknown|2023Cited by 0
Supplementary Figure 2 from Oncolytic Herpes Virus Armed with Vasculostatin in Combination with Bevacizumab Abrogates Glioma Invasion via the CCN1 and AKT Signaling PathwaysYusuke Tomita, Isao Date, Kazuhiko Kurozumi et al.|Unknown|2023Cited by 0
Supplementary Figure 1 from Oncolytic Herpes Virus Armed with Vasculostatin in Combination with Bevacizumab Abrogates Glioma Invasion via the CCN1 and AKT Signaling PathwaysYusuke Tomita, Isao Date, Kazuhiko Kurozumi et al.|Unknown|2023Cited by 0